Gainers
- TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 16.5% to $0.74 during Wednesday's after-market session. Trading volume for this security closed at 344.0K, accounting for 28.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.7 million.
- Solid Biosciences (NASDAQ:SLDB) shares rose 15.87% to $0.59. The market value of their outstanding shares is at $66.4 million.
- Minerva Neurosciences (NASDAQ:NERV) shares rose 9.92% to $0.4. The market value of their outstanding shares is at $17.1 million.
- Biotricity (NASDAQ:BTCY) stock moved upwards by 9.09% to $1.2. The company's market cap stands at $61.6 million.
- Trevena (NASDAQ:TRVN) shares rose 8.74% to $0.24. The market value of their outstanding shares is at $39.7 million.
- AcelRx Pharmaceuticals (NASDAQ:ACRX) stock increased by 8.64% to $0.25. The company's market cap stands at $36.7 million.
Losers
- Genocea Biosciences (NASDAQ:GNCA) shares declined by 13.1% to $0.08 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 39.3 million shares, which is 1133.4 percent of its average volume over the last 100 days. The company's market cap stands at $4.7 million.
- SpringWorks Therapeutics (NASDAQ:SWTX) shares fell 5.06% to $31.02. The company's market cap stands at $1.5 billion.
- Motus GI Hldgs (NASDAQ:MOTS) stock decreased by 5.01% to $0.28. This security traded at a volume of 4.7 million shares come close, making up 821.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $15.6 million.
- icad (NASDAQ:ICAD) stock decreased by 4.88% to $3.32. The market value of their outstanding shares is at $83.6 million.
- BioXcel Therapeutics (NASDAQ:BTAI) stock declined by 4.72% to $10.91. The company's market cap stands at $305.3 million.
- Mirum Pharmaceuticals (NASDAQ:MIRM) shares declined by 4.71% to $24.49. The company's market cap stands at $779.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
